[(1)N,(12)N]双（乙基）-顺式-6,7-脱氢精胺：一种用于治疗和预防T细胞受体α缺陷小鼠隐孢子虫感染的新药。
[(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.
作者信息
Waters W R, Frydman B, Marton L J, Valasinas A, Reddy V K, Harp J A, Wannemuehler M J, Yarlett N
机构信息
Bacterial Diseases of Livestock Unit, National Animal Disease Center, Agricultural Research Service, U.S. Department of Agriculture, Ames, Iowa 50010, USA.
出版信息
Antimicrob Agents Chemother. 2000 Oct;44(10):2891-4. doi: 10.1128/AAC.44.10.2891-2894.2000.
Abstract
Cryptosporidium parvum infection of T-cell receptor alpha (TCR-alpha)-deficient mice results in a persistent infection. In this study, treatment with a polyamine analogue (SL-11047) prevented C. parvum infection in suckling TCR-alpha-deficient mice and cleared an existing infection in older mice. Treatment with putrescine, while capable of preventing infection, did not clear C. parvum from previously infected mice. These findings provide further evidence that polyamine metabolic pathways are targets for new anticryptosporidial chemotherapeutic agents.
摘要
微小隐孢子虫感染T细胞受体α（TCR-α）缺陷小鼠会导致持续性感染。在本研究中，用一种多胺类似物（SL-11047）治疗可预防乳鼠期TCR-α缺陷小鼠感染微小隐孢子虫，并清除老年小鼠体内已有的感染。用腐胺治疗虽能预防感染，但不能清除先前感染小鼠体内的微小隐孢子虫。这些发现进一步证明多胺代谢途径是新型抗隐孢子虫化疗药物的作用靶点。
相似文献
1
[(1)N,(12)N]Bis(Ethyl)-cis-6,7-dehydrospermine: a new drug for treatment and prevention of Cryptosporidium parvum infection of mice deficient in T-cell receptor alpha.
Antimicrob Agents Chemother. 2000 Oct;44(10):2891-4. doi: 10.1128/AAC.44.10.2891-2894.2000.
2
Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.
Antimicrob Agents Chemother. 2007 Apr;51(4):1234-9. doi: 10.1128/AAC.01040-06. Epub 2007 Jan 22.
3
Cryptosporidium parvum-induced inflammatory bowel disease of TCR-beta- x TCR-delta-deficient mice.
J Parasitol. 1999 Dec;85(6):1100-5.
4
Efficacy of chitosan, a natural polysaccharide, against Cryptosporidium parvum in vitro and in vivo in neonatal mice.
Exp Parasitol. 2018 Nov;194:1-8. doi: 10.1016/j.exppara.2018.09.003. Epub 2018 Sep 17.
5
6
B cells are required for the induction of intestinal inflammatory lesions in TCRalpha-deficient mice persistently infected with Cryptosporidium parvum.
J Parasitol. 2000 Oct;86(5):1073-7. doi: 10.1645/0022-3395(2000)086[1073:BCARFT]2.0.CO;2.
7
Bobel-24 activity against Cryptosporidium parvum in cell culture and in a SCID mouse model.
Antimicrob Agents Chemother. 2008 Mar;52(3):1150-2. doi: 10.1128/AAC.01019-07. Epub 2007 Dec 26.
8
A cysteine protease inhibitor rescues mice from a lethal Cryptosporidium parvum infection.
Antimicrob Agents Chemother. 2013 Dec;57(12):6063-73. doi: 10.1128/AAC.00734-13. Epub 2013 Sep 23.
9
Accelerated inflammatory bowel disease of TCR-alpha-deficient mice persistently infected with Cryptosporidium parvum.
J Parasitol. 1997 Jun;83(3):460-4.
10
Effects of Lactobacillus reuteri on Cryptosporidium parvum infection of gnotobiotic TCR-alpha-deficient mice.
J Eukaryot Microbiol. 1999 Sep-Oct;46(5):60S-61S.
引用本文的文献
1
Design of polyamine-based therapeutic agents: new targets and new directions.
Essays Biochem. 2009 Nov 4;46:77-94. doi: 10.1042/bse0460006.
2
Recent advances in the development of polyamine analogues as antitumor agents.
J Med Chem. 2009 Aug 13;52(15):4551-73. doi: 10.1021/jm900187v.
3
Therapeutic evaluation of polyamine analogue drug candidates against Enterocytozoon bieneusi in a SCID mouse model.
Antimicrob Agents Chemother. 2009 Jun;53(6):2417-23. doi: 10.1128/AAC.01113-08. Epub 2009 Mar 16.
4
In vitro and in vivo effects of the conformationally restricted polyamine analogue CGC-11047 on small cell and non-small cell lung cancer cells.
Cancer Chemother Pharmacol. 2008 Dec;63(1):45-53. doi: 10.1007/s00280-008-0706-x. Epub 2008 Feb 27.
5
Activities of DL-alpha-difluoromethylarginine and polyamine analogues against Cryptosporidium parvum infection in a T-cell receptor alpha-deficient mouse model.
Antimicrob Agents Chemother. 2007 Apr;51(4):1234-9. doi: 10.1128/AAC.01040-06. Epub 2007 Jan 22.
6
Efficacy of monoclonal antibodies against defined antigens for passive immunotherapy of chronic gastrointestinal cryptosporidiosis.
Antimicrob Agents Chemother. 2002 Feb;46(2):275-82. doi: 10.1128/AAC.46.2.275-282.2002.
本文引用的文献
1
Conformationally restricted analogues of 1N,12N-bisethylspermine: synthesis and growth inhibitory effects on human tumor cell lines.
J Med Chem. 1998 Nov 19;41(24):4723-32. doi: 10.1021/jm980172v.
2
Cryptosporidiosis: laboratory investigations and chemotherapy.
Adv Parasitol. 1998;40:187-221. doi: 10.1016/s0065-308x(08)60121-9.
3
Manure and microbes: public and animal health problem?
J Dairy Sci. 1997 Oct;80(10):2673-81. doi: 10.3168/jds.S0022-0302(97)76227-1.
4
Spermine induces maturation of the immature intestinal immune system in neonatal mice.
J Pediatr Gastroenterol Nutr. 1997 Sep;25(3):332-40. doi: 10.1097/00005176-199709000-00017.
5
Polyamine biosynthesis in Cryptosporidium parvum and its implications for chemotherapy.
Mol Biochem Parasitol. 1997 Sep;88(1-2):35-42. doi: 10.1016/s0166-6851(97)00063-7.
6
7
The effect of cotrimoxazole on experimental Cryptosporidium parvum infection in kids.
Vet Res. 1997 Jul-Aug;28(4):405-12.
8
Accelerated inflammatory bowel disease of TCR-alpha-deficient mice persistently infected with Cryptosporidium parvum.
J Parasitol. 1997 Jun;83(3):460-4.
9
Environmental ecology of Cryptosporidium and public health implications.
Annu Rev Public Health. 1997;18:135-61. doi: 10.1146/annurev.publhealth.18.1.135.
10
Efficacy of 101 antimicrobials and other agents on the development of Cryptosporidium parvum in vitro.
Ann Trop Med Parasitol. 1996 Dec;90(6):603-15. doi: 10.1080/00034983.1996.11813090.
Zotero 插件